Free Research Report as Johnson & Johnson's Quarterly Earnings Advanced 14.75%

LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Johnson & Johnson most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=JNJ

Earnings Highlights and Summary

For Q2 FY18, JNJ’s total worldwide sales reached $20.83 billion, reflecting an increase of 10.57% from $18.84 billion in Q2 FY17. This was led a double-digit growth in the Company’s Pharmaceutical business and the accelerating sales momentum in its Medical Devices business, driven by the continued growth of market leading products and strategic new launches. The Company’s total revenue numbers exceeded analysts’ consensus estimates by $440 million.

During the quarter under review, JNJ’s US sales increased 9.40% to $10.64 billion on a y-o-y basis, while its international sales jumped 11.82% to $10.19 billion on a y-o-y basis. The Company’s total reported worldwide sales included the impact of acquisitions and divestitures. Excluding the net impact of acquisitions and divestitures, JNJ’s worldwide sales increased 6.30%; its domestic sales increased 5.70%; and its international sales increased 6.80% on an operational basis in Q2 FY18 versus Q2 FY17.

During Q2 FY18, JNJ’s cost of products sold was $6.93 billion, 18.47% higher than $5.85 billion in Q2 FY17. The Company’s gross profit advanced 7% to $13.90 billion in the reported quarter from $12.99 billion in the previous year’s comparable quarter.

JNJ incurred selling, marketing, and administrative expenses of $5.74 billion in Q2 FY18, up 8.58% from $5.29 billion in Q2 FY17. For the reported quarter, the Company’s research and development (R&D) expenses jumped 14.94% to $2.64 billion on a y-o-y basis. JNJ’s earnings before provision for taxes were $4.97 billion in Q2 FY18 compared to $4.75 billion in Q2 FY17, reflecting an increase of 4.74%.

JNJ’s net earnings were $3.95 billion in Q2 FY18, up 3.32% from $3.83 billion in Q2 FY17. The Company’s diluted earnings per share (EPS) also advanced 3.57% to $1.45 in Q2 FY18 from $1.40 in Q2 FY17. The Company’s reported results included intangible asset amortization expenses, litigation expenses, restructuring expenses, and AMO acquisition-related costs. JNJ’s adjusted diluted EPS, excluding these non-recurring items, were $2.10 in Q2 FY18, up 14.75% from $1.83 in Q2 FY17. This exceeded analysts’ consensus estimates by $0.03 per share. On an operational basis, excluding the impact of foreign currency exchange rates, the Company’s adjusted diluted EPS increased 11.50% on a y-o-y basis.

Segment Details

During Q2 FY18, JNJ’s Consumer segment’s worldwide sales were $3.50 billion, reflecting an increase of 0.75% from $3.48 billion in Q2 FY17. This included an operational decrease of 0.40% and a positive impact from currency of 1.10%. For the reported quarter, the Consumer segment’s US sales declined 0.74% to $1.48 billion on a y-o-y basis, while its International sales ascended 1.86% to $2.03 billion on a y-o-y basis. The segment had an adjusted income before tax of $902 million in Q2 FY18 compared to $714 million in Q2 FY17, reflecting an increase of 26.33%.

JNJ’s Pharmaceutical segment reported worldwide sales of $10.35 billion in Q2 FY18, 19.91% higher than in the previous year’s same quarter. This included an operational increase of 17.60% and a positive impact from currency of 2.30%. During the reported quarter, the segment’s US sales increased 17.74% to $5.90 billion on a y-o-y basis and its international sales jumped 22.90% to $4.46 billion on a y-o-y basis. The segment had an adjusted income before tax of $4.48 billion in Q2 FY18, 16.44% higher than $3.85 billion in Q2 FY17.

During Q2 FY18, JNJ’s Medical Devices segment generated worldwide sales of $6.97 billion, 3.66% higher than in the year ago comparable quarter. This consisted of an operational increase of 1.90% and a positive currency impact of 1.80%. During the second quarter of the fiscal year 2018, the segment’s US sales advanced 1.11% to $3.27 billion on a y-o-y basis and its international sales increased 6.01% to $3.71 billion on a y-o-y basis. The segment had an adjusted income before tax of $1.94 billion in Q2 FY18, 5.09% lower than $2.04 billion in Q2 FY17.

Stock Performance Snapshot

July 18, 2018 - At Wednesday’s closing bell, Johnson & Johnson’s stock fell 1.01%, ending the trading session at $127.80.

Volume traded for the day: 6.99 million shares, which was above the 3-month average volume of 6.65 million shares.

Stock performance in the last month – up 5.34%; and previous three-month period – up 0.06%

After yesterday’s close, Johnson & Johnson’s market cap was at $343.62 billion.

Price to Earnings (P/E) ratio was at 23.57.

The stock has a dividend yield of 2.82%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.2% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA^® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors